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Background: In-centre haemodialysis (ICHD) is the most common dialysis method used by patients worldwide.
However, quality of life and clinical outcomes in patients treated via ICHD have not improved for some time.
‘High-dose’ haemodialysis (HD) regimens – which are longer and/or more frequent than conventional regimens
and are particularly suitable to delivery in the home – may offer a route to improved outcomes and quality of life.
This survey aimed to determine nephrologists’ views on the validity of alternatives to ICHD, particularly home HD
and high-dose HD.
Methods: A total of 1,500 nephrologists from Europe, Canada and the United States were asked to respond to an
online questionnaire that was designed following previous qualitative research. Certified nephrologists in practice
for 2–35 years who managed >25 adult dialysis patients were eligible to take part.
Results: A total of 324 nephrologists completed the survey. ICHD was the most common type of dialysis used by
respondents’ current patients (90%), followed by peritoneal dialysis (8%) and home HD (2%). The majority of
respondents believed that: home HD provides better quality of life; increasing the frequency of dialysis beyond
three times per week significantly improves clinical outcomes; and longer dialysis sessions performed nocturnally
would result in significantly better clinical outcomes than traditional ICHD.
Conclusions: Survey results indicated that many nephrologists believe that home HD and high-dose HD are better
for the patient. However, the majority of their patients were using ICHD. Education, training and support on
alternative dialysis regimens are needed.
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End-stage renal disease (ESRD) places a considerable
burden on healthcare resources [1]. Over 2 million people
worldwide currently require treatment for ESRD [2]. In
2009, over 1 million patients received renal replacement
therapy (RRT) in the USA and Europe combined [3,4].
Despite technological advances in haemodialysis (HD)
over the past 2 decades, clinical outcomes remain poor
and high rates of morbidity and mortality persist [5]. In
the USA, HD patient survival rates have barely improved
in more than 25 years and, in 2009, only 50% of dialysis
patients were expected to survive 3 years after the start of
ESRD therapy [3]. In addition to the lack of progress in* Correspondence: richard.fluck@nhs.net
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reproduction in any medium, provided the orsurvival rates, the quality of life of patients on HD has not
improved [6].
In-centre HD (ICHD), generally performed thrice-
weekly for 4 to 5 hours per session, is the most common
dialysis option used by patients worldwide [3]. However,
the latest USRDS report shows that 33.6% of HD patients
in the US receive only 180 minutes of dialysis or less per
session [7]. Alternative, home-based dialysis options in-
clude peritoneal dialysis (PD) and home HD. While not
true for all patients [8-10], generally, PD and conventional
home HD offer clinical outcomes that are equivalent, and
in some patient groups superior, to those provided by
ICHD [11-15]. However, patients using home dialysis
benefit from greater independence and autonomy, and
less intrusion into their everyday lives [13,16,17]. Further-
more, reduced travel, support, service and collateral coststd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Number of participating nephrologists and mean
number of dialysis patients per respondent by country
Number (%) of
participating nephrologists
Mean (± SD) number
of adult dialysis patients
treated per nephrologist
Canada 46 (14.2) 168.0 (118.3)
France 47 (14.5) 97.1 (48.2)
Germany 31 (9.6) 109.0 (51.2)
UK 50 (15.4) 342.7 (208.5)
USA 150 (46.3) 128.4 (109.7)
SD, Standard deviation.
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clinical benefit at reasonable or even reduced costs
[12,18]. Home HD has the added benefit of facilitating
frequent and/or longer ‘high-dose’ HD regimens such as
nocturnal HD and short-daily HD. Such regimens lack
the long (2-day) interdialytic interval associated with
conventional HD, which has been shown to increase pa-
tient mortality risk [19]. In contrast, high-dose HD regi-
mens have shown significant physiological, clinical and
patient-reported advantages over conventional ICHD
[20-30]. Despite their apparent benefits, home dialysis
options remain the less popular choices in many coun-
tries [3]. In light of the apparent disconnect between the
possible advantages and actual uptake of home dialysis,
a multinational survey of nephrologists was undertaken
to determine nephrologists’ views on home dialysis op-
tions, with a particular focus on home HD and high-
dose HD.
Methods
Nephrologists from Canada, France, Germany, the United
Kingdom and the United States were asked to respond
to an online questionnaire that took around 45 minutes
to complete. The invitation to participate was sent elec-
tronically to a list of 1,500 known nephrologists within
the participating countries. Questionnaires developed in
English and translated into appropriate languages for
nephrologists in France and Germany were completed
by respondents in the second half of 2010. Respondents
were paid a fee to complete the questionnaire in line
with currently acceptable standards for such research.
The first part of the questionnaire contained questions
used to determine whether the responder was eligible to
take part in the survey. Only certified nephrologists who
had been in practice for 2–35 years and who currently
managed more than 25 adult dialysis patients on any
modality were eligible for inclusion in the survey ana-
lysis. Responders were not included if they currently
served as a consultant, advisory board member or em-
ployee of a pharmaceutical company, medical device
company or other healthcare manufacturer; or had par-
ticipated in dialysis market research within the past
month.
The second part of the questionnaire was designed to
obtain nephrologists’ beliefs and attitudes around dialy-
sis modalities and prescriptions, and current treatment
goals. Questions were chosen based on previous, unpub-
lished qualitative research performed in the five afore-
mentioned countries. The qualitative research explored
the beliefs and values of nephrologists and nurses to-
wards dialysis in general and home dialysis options in
particular, and was performed using a variety of research
techniques, including in-person, in-depth interviews and
in-depth interviews by telephone. Interviews lasted from45–120 minutes and provided directional information to
structure the quantitative questionnaire.
Nephrologists were asked to respond to a variety of
statements using the following scale: strongly disagree;
disagree; somewhat disagree; somewhat agree; agree;
strongly agree. Specifically, questions were asked to
discover nephrologists’ personal motivations for treat-
ing chronic kidney disease or dialysis patients, treat-
ment goals, attitudes towards new therapies, attitudes
towards guidelines and policies, attitudes towards dia-
lysis modalities, and reasons for selecting particular
dialysis modalities. In the third section of the question-
naire, the physicians were asked to summarise the dia-
lysis modalities used by their patients, and also general
patient capabilities and health profiles. In the final section,
different patient profiles were described (relatively healthy;
moderately healthy; chronically unhealthy) and nephrolo-
gists were asked to provide their dialysis modality recom-
mendations for each profile. This was an extensive survey
and the questions most relevant to physicians’ dialysis mo-
dality selection are reported herein (see Additional file 1).
Results were analysed using Excel and presented as
descriptive statistics. Data are presented as mean num-
bers ± standard deviation, or as percentages. Unless
otherwise stated, all respondents who indicated ‘strongly
agreed’ or ‘agreed’ are presented together in the text as
the proportion of respondents who agreed with a par-
ticular statement.
Ethics approval was not sought for this online survey
of healthcare staff; consent to participate in the survey




A total of 324 nephrologists from five countries com-
pleted the survey; almost half of all participants came
from the USA (Table 1). On average, clinicians spent
57.2% of their time working in hospitals (ranging from
19.5% in Germany to 98.4% in the UK) and 34.3% of
their time in private practice (ranging from 0.5% in the
UK to 65.3% in Germany). Mean values for the
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treated (per respondent) ranged from 97.1 (±48.2) in
France to 342.7 (±208.5) in the UK (Table 1). Overall,
participants had a mean of 14.1 ± 7.5 years of nephrology
practice (excluding time as a trainee). Approximately
20% of patients currently attending responders’ clinics
had started dialysis in the last year.
Characteristics of dialysis prescription by nephrologists
ICHD was the most common type of dialysis prescribed.
Overall, nephrologists reported that 90% of their patients
were on ICHD; PD (8%) and home HD (2%) were much
less commonly used. This predominance of ICHD was
observed across all five countries (Figure 1). The propor-
tions of nephrologists who reported that their dialysis
clinic did not offer home HD varied from 8% in the UK
to 36% in France, and the proportions of nephrologists
reporting that their clinic did not offer PD varied be-
tween 4% (UK and USA) and 19% (Germany) (Table 2).
Nephrologists’ attitudes to treatment goals and dialysis
prescribing
Overall, 35% of nephrologists agreed or strongly agreed
with the statement that “improving patients’ quality of life
is more important to me than helping them live longer”.
When nephrologists who stated they somewhat agreed
with this statement were included, 76% of nephrologists
were shown to favour quality of life improvements versus
increased survival (Figure 2A). Approximately 61% of
nephrologists agreed that home HD gives a better qual-
ity of life than ICHD and 47% agreed that ICHD pa-
tients find it a burden to travel to the clinic three times
each week (Figure 2A). The majority also agreed that in-
creasing the frequency of dialysis beyond three times
per week significantly improves clinical outcomes
(59%), and that longer dialysis sessions performed noc-

























Figure 1 Proportion of patients receiving different forms of dialysis t
haemodialysis; PD, peritoneal dialysis, n = number of respondents per cououtcomes than traditional ICHD (69%) (Figure 2B).
Only 12% of nephrologists agreed that they preferred their
patients to have ICHD because it allowed closer monitor-
ing of their condition (Figure 2B). A total of 61% of re-
spondents thought that home HD was under-prescribed
and 62% thought that PD was under-prescribed. Only 8%
of responders agreed that they needed to see more clinical
data before prescribing home HD. Overall, nephrologists’
attitudes towards different dialysis modalities were similar
across all five countries (Figure 2A and B).
Nephrologists’ recommendations on dialysis
Patient health was important in treatment recommenda-
tion in all countries. Over half of nephrologists (56%)
agreed to some extent (strongly agree; agree; somewhat
agree) that they would recommend home HD or PD
only to their healthiest patients. Family and home status
was also an important factor; 45% of nephrologists agreed
that patients must have a care partner before they would
prescribe home HD. Respondents estimated that as many
as 35% of their patients had no care partner.
Half the nephrologists (50%) stated that home HD was
their preferred treatment option and 63% said they would
recommend it to the majority of their close family or
friends. In contrast to this, use of a range of fictional pa-
tient case studies showed that the greater proportion of
respondents in all countries except Canada would recom-
mend ICHD rather than home HD to a patient who was
relatively healthy and new to dialysis (Figure 3A). When
presented with a fictional patient in relatively poor health
already on ICHD, the majority of responders in all coun-
tries stated that they would expect the patient to still be
on ICHD in one year’s time (Figure 3B).
Discussion
A recent paper has highlighted four areas of benefit to







reatment by country. HHD, home haemodialysis; ICHD, in-centre
ntry.
Table 2 Home HD and PD availability across each country
Home HD not offered in
dialysis clinic/unit (% [n])
PD not offered in dialysis
clinic/unit (% [n])
Canada 13 (6/46) 9 (4/46)
France 36 (17/47) 13 (6/47)
Germany 23 (7/31) 19 (6/31)
UK 8 (4/50) 4 (2/50)
USA 18 (27/150) 4 (6/150)
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decreased sick role (including return to regular employ-
ment) and 4. identification of competencies to undertake
self-care [31]. In support of this, our study showed that
most participating nephrologists would prefer to prescribe
home dialysis. Most nephrologists who responded to the
survey believed that home HD provides a better quality of
life than ICHD. In addition, most stated that they would
recommend home HD as a dialysis treatment to their
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Figure 2 Nephrologists’ attitudes towards different dialysis modalitie
modalities on (A) quality of life and (B) clinical outcomes. HHD, home haem
PD, peritoneal dialysis.were under-prescribed. Despite such apparently over-
whelming support for home dialysis from respondents,
this survey also showed that the vast majority of dialysis
patients under respondents’ care currently receive ICHD.
Furthermore, investigation into which dialysis modality re-
spondents would recommend for patients with different
health profiles revealed that, despite preferring home dia-
lysis, most nephrologists in France, Germany, the UK and
the USA would still recommend ICHD to patients, re-
gardless of health status or history of dialysis. However, it
was noted that a slightly greater proportion of respon-
dents would recommend home HD and PD if the patient
was relatively healthy and new to dialysis. Over half of re-
spondents agreed to some extent that they would recom-
mend home HD or PD only to their healthiest patients.
The majority of respondents considered that increasing
the frequency of dialysis beyond three times per week and
performing longer nocturnal dialysis sessions significantly
improves clinical outcomes. These beliefs are consistent
with evidence from clinical studies indicating that high-Nephrologists’ responses (% )
40 60 80 100
mewhat  disagree Disagree Strongly  disagree
mewhat  disagree Disagree Strongly  disagree
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s. Responses to statements around the effects of different dialysis
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Figure 3 Nephrologists’ dialysis recommendations to patients in fictional case studies. (A) Patient has relatively good health and is new to
dialysis; (B) Patient has relatively poor health and is already on ICHD. HHD, home haemodialysis; ICHD, in-centre haemodialysis; PD, peritoneal
dialysis. *Self-care HD = patients attend outpatient facilities with no/very limited nurse supervision and no attending doctor (France only).
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physiological markers and clinical and patient-reported
outcomes versus conventional ICHD. For example, pa-
tients on high-dose HD regimens exhibit improved urea
clearance [20-22], lower phosphate levels and use of
phosphate-binding medications [22,25,26], greater blood
pressure control [22-24] and reduced left ventricular mass
[24,25] versus those on ICHD. Patients receiving high-
dose HD also report an improved perception of their
general health and mental health and a reduction in the
impact of disease on their lives [27-30]. Survival data are
relatively scarce, but two small retrospective, observational
studies have reported better survival for patients on noc-
turnal HD versus those on ICHD [32,33]. A retrospective
matched-cohort study also reported a 45% improvement
in survival with high-dose HD in the home versus thrice-
weekly ICHD [34]. Daily home HD has also been associ-
ated with a 13% lower risk for all-cause mortality than
conventional ICHD performed three times weekly [35].
Two main questions arise following our survey: why is
there a large discrepancy between nephrologists’ treat-
ment preferences and their prescribing habits, and what
can be done to reduce it? One likely factor is treatment
availability; for example, up to a third of the respon-
dents’ dialysis clinics did not offer home HD, although
this reduced to up to a sixth of respondents for PD. In
the surveyed countries, ICHD is the standard treatment
option, and it may be more difficult for a clinician to
prescribe an alternative. One study showed that the use
of home HD in the USA was influenced by the number
of treatments covered by Medicare [36]. In an Australian
study, lack of physical clinic infrastructure and training
facilities were among the reasons cited by nephrologists
as barriers to the uptake of home HD [37]. In some
countries PD is the standard method of dialysis and in-
frastructure is well developed to support this. Therefore,
the discrepancy between nephrologists’ home dialysis
preferences and prescribing practices in these countries
may be less pronounced [17].Our results show there appears to be a perception
among the respondents that home HD and PD should be
used only in patients who are relatively young and healthy.
Comorbid conditions can influence the best type of dialy-
sis modality to use. For example, if a patient has multiple
comorbidities or suffers from frequent complications dur-
ing HD, then ICHD under medical supervision may be ne-
cessary [17]. Similarly, patients with diabetes or comorbid
heart conditions are more likely to use PD than home HD
[38]. However, it is not always the case that healthier,
younger patients are best suited to home dialysis; with ad-
equate support, older patients with comorbidities can fare
well on home HD or PD [39]. Studies further profiling
which patients benefit most from home HD may help ne-
phrologists when recommending different dialysis modal-
ities to their patients.
Several studies have been published investigating health-
care provider and patient attitudes towards different
methods of HD care and delivery, including home HD
[37,40-42]. A report investigating home HD in the
USA categorised the impediments to its effective delivery
into educational barriers (for patients and healthcare pro-
viders), governmental/regulatory barriers (state and fed-
eral), and barriers specifically related to the philosophies
and business practices of dialysis providers (e.g. staffing,
supplies and continuous quality improvement practices)
[43]. In Australia, nephrologists felt healthcare system fac-
tors such as inadequate funding for home therapies in the
private sector, lack of financial incentives in the public sec-
tor, limited psychological outreach support for patients
and carers, lack of training facilities and opportunities for
staff and patients, and lack of available simple home dialy-
sis technology prevented the increased uptake of home
HD [37]. Nephrologists and nurses believed that patients
might also be worried about the personal costs of home
HD, even though many costs (such as the financial burden
of travelling to a clinic) are actually reduced with home
HD [12,17,37,40]. Patient attitude and lack of confidence
and motivation were also cited as barriers, especially if
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been on dialysis for a long time [37,40].
In countries such as Australia, Finland and the UK
where the uptake of home HD is relatively high, success
has been attributed to provision of adequate funding, sup-
port, education and training to both service users and ser-
vice providers in the use of home HD [17,44,45]. In
Australia, nephrologists believed that medical and nursing
expertise in home dialysis was good, that home HD was
available and supported by most units, and that longer
hours and/or more frequent regimens offered outcome
advantages [37]. At the Helsinki University Hospital in
Finland, adoption of a ‘home first’ policy in predialysis
education, close cooperation with other dialysis centres
and centralised home HD training to support remote hos-
pitals were cited as key factors for establishing an effective
home HD programme [44]. Strong clinical leadership ap-
pears to be key in the UK, with the need to challenge be-
liefs about who might be suitable for home HD emerging
as a consistent theme for improving patient access to
home HD [45]. Additional considerations for successful
home HD programmes, raised by the American Society of
Nephrology Dialysis Advisory Group, include: selection of
appropriate dialysis machines for the treatment regimen,
differences in prescribed regimens e.g. dialysate flow; reli-
able vascular access, preferably arteriovenous fistulas; the
potential requirement for remote monitoring, and finally,
patient burnout necessitating return to ICHD or a period
of ‘respite’ care [46]. Further initiatives to establish inte-
grated home HD pathways, develop financial incentives
and solutions to sustainability challenges, provide support
for carers, and capture key indicators of dialysis use and
practices within renal registries are also required [18,45].
Initiatives such as telemedicine (i.e. telephone support lines
and other information technology applications) to provide
medical support for patients at home could help improve
safety and reassure patients on home HD [42].
The results of this survey must be interpreted in light
of its limitations. Generally speaking, a survey can cap-
ture only broad perspectives. Views on complex issues
are difficult to compress into simple answers and the
questionnaire could not capture all the nuances of ne-
phrologists’ treatment decisions. In France, for example,
funding for a nurse to provide assisted PD is available to
patients, from which elderly patients who would other-
wise be on ICHD can benefit. Therefore, this is likely to
influence French nephrologists’ treatment recommen-
dations. It should also be recognised that respondents’
answers to interview questions may differ from their
true beliefs. In addition, although encompassing five
countries, the study results were biased towards expe-
riences of US nephrologists, as the number of USA re-
spondents was around three times greater than for
other countries. Outside the USA, only a relatively smallnumber of respondents (≤50) were recruited from each
country. It should also be noted that the survey did not
include respondents from Australia and New Zealand,
countries where home therapies are most common.
Data from a larger, more comprehensive group of ne-
phrologists, along with appropriate statistical analysis,
would help further elucidate worldwide practices and
preferences in dialysis treatment. Finally, the process of
recruiting survey respondents may have itself biased the
study population in some way, perhaps recruiting only
the most enthusiastic professionals. Therefore, survey re-
sults may not fully portray the full spectrum of ne-
phrologists’ attitudes. Of note, in another international
survey comprising 544 respondents, physician atti-
tudes toward the evidence for high-dose HD differed
significantly between those who typically had patients
on high-dose HD and conventional ICHD providers
[47]. High-dose HD providers were significantly more
likely to agree with statements that such regimens im-
prove quality of life, improve nutritional status, reduce
erythropoietin requirements and are cost effective com-
pared with ICHD providers [47].
Conclusions
In summary, this survey revealed a high level of support
for home therapies, including home HD. Despite this,
most patients under the respondents’ care are treated by
ICHD, consistent with the generally low uptake of home
HD in clinical practice. While lack of access may par-
tially explain these low uptake rates, nephrologists may
be excluding certain types of patients from home therap-
ies (e.g. older patients, individuals with comorbidities)
who could actually benefit from options other than ICHD.
Provision of more support, training and education to ne-
phrologists and other members of the multi-professional
team is needed to increase clinicians’ knowledge of, and
confidence in, the suitability of home HD for the wider
patient population. Such training and education must be
embedded into the professional curriculum and should
encompass the relative merits of all modalities including
the specifics of home therapies in both training and
ongoing care. In centres not offering home therapies,
trainees and established clinicians should be offered fel-
lowships or other opportunities to learn about home treat-
ments. Shared decision making between clinical teams
and their patients should also be improved. In addition,
new incentives to drive changes in national healthcare
policies may be needed.Additional file
Additional file 1: Questionnaire. Survey questions relevant to
physicians’ dialysis modality selection.
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